11.28.14
Vantage Health has a new leader.
Kevin Buckman, M.D., has been appointed chairman/CEO of the company. His predecessor, Jeremy Barbera, resigned to focus on the scientific aspects of the company’s technology in a non-executive capacity. Barbera will continue to be chairman and CEO of Nanobeak, the private company majority shareholder of Vantage Health.
Buckman completed his medical training in internal medicine in 1981. He began his research in 1977 in the fields of immunology, cancer, diabetes, and chronic diseases. His discoveries of the roles of inflammation and abnormal cellular environments in cancers and immune diseases have made him renowned in the field. His research has led to his interest in technologies in early diagnosis and treatments, especially in the field of breast cancer. He recently published a book on the subject, Find and Stop Breast Cancer, as well as a book on solutions for diabetes and metabolic syndrome, titled Find and Stop Diabetes. He has worked internationally to advance a number of medical technologies with a focus on early detection of disease, with a primary focus on breast cancer and diabetes.
Buckman has served as medical director in various hospitals and institutions for more than 25 years and has more than 30 years of hospital and clinical experience. He became board certified in emergency medicine and a Fellow of the American Board of Emergency Medicine in 1990. In 2006 he became board certified in urgent care medicine and a diplomat. He also became a Fellow of the American Association of Integrated Medicine, and a certified medical review officer.
Buckman was the first U.S. physician to be accepted into the European group for breast cancer screening. He received some post-graduate training at Stanford University School of Business. He also is the Co-Founder of cancer.im, a 501(c)(3) non-profit organization for cancer research. In addition, Buckman serves as CEO of Viratech Corp., which provides open source research using social networks.
Vantage Health, a mobile health technology company, develops personalized and point-of-care screening using apps based upon chemical sensing residing within a small device attached to a smartphone. With its foundations in advanced nanotechnology, the company’s first product, the Vantage Health Sensor, is the convergence of nano-electronics, bio-informatics, and wireless technology to create the next-generation mobile health application. The first mobile app is expected to be for lung cancer screening with additional mobile healthcare apps in the planning stages. The company has offices in Redwood City, Calif., and New York, N.Y.
Kevin Buckman, M.D., has been appointed chairman/CEO of the company. His predecessor, Jeremy Barbera, resigned to focus on the scientific aspects of the company’s technology in a non-executive capacity. Barbera will continue to be chairman and CEO of Nanobeak, the private company majority shareholder of Vantage Health.
Buckman completed his medical training in internal medicine in 1981. He began his research in 1977 in the fields of immunology, cancer, diabetes, and chronic diseases. His discoveries of the roles of inflammation and abnormal cellular environments in cancers and immune diseases have made him renowned in the field. His research has led to his interest in technologies in early diagnosis and treatments, especially in the field of breast cancer. He recently published a book on the subject, Find and Stop Breast Cancer, as well as a book on solutions for diabetes and metabolic syndrome, titled Find and Stop Diabetes. He has worked internationally to advance a number of medical technologies with a focus on early detection of disease, with a primary focus on breast cancer and diabetes.
Buckman has served as medical director in various hospitals and institutions for more than 25 years and has more than 30 years of hospital and clinical experience. He became board certified in emergency medicine and a Fellow of the American Board of Emergency Medicine in 1990. In 2006 he became board certified in urgent care medicine and a diplomat. He also became a Fellow of the American Association of Integrated Medicine, and a certified medical review officer.
Buckman was the first U.S. physician to be accepted into the European group for breast cancer screening. He received some post-graduate training at Stanford University School of Business. He also is the Co-Founder of cancer.im, a 501(c)(3) non-profit organization for cancer research. In addition, Buckman serves as CEO of Viratech Corp., which provides open source research using social networks.
Vantage Health, a mobile health technology company, develops personalized and point-of-care screening using apps based upon chemical sensing residing within a small device attached to a smartphone. With its foundations in advanced nanotechnology, the company’s first product, the Vantage Health Sensor, is the convergence of nano-electronics, bio-informatics, and wireless technology to create the next-generation mobile health application. The first mobile app is expected to be for lung cancer screening with additional mobile healthcare apps in the planning stages. The company has offices in Redwood City, Calif., and New York, N.Y.